Clinical trials involving the KRAS G12C inhibitors sotorasib and adagrasib demonstrated modest response rates and PFS in lung cancer patients carrying this mutation (28% and 43%, and 5.6 months and 6.5 months, respectively) [99,100]. This evidence concerns the gene KRAS and lung carcinoma.